神经胶质瘤,miR-122,RUNX2,凋亡 ," /> 神经胶质瘤,miR-122,RUNX2,凋亡 ,"/> <p class="MsoNormal" style="text-align:justify;"> miR-122通过靶向RUNX2诱导胶质瘤细胞凋亡的实验研究

临床肿瘤学杂志 ›› 2019, Vol. 24 ›› Issue (2): 124-128.

• • 上一篇    下一篇

miR-122通过靶向RUNX2诱导胶质瘤细胞凋亡的实验研究

  

  1. 1  610100  成都  四川省医学科学院 四川省人民医院神经内科

    2  610100  四川省医学科学院 四川省人民医院(东院)肿瘤内科

  • 收稿日期:2018-11-02 修回日期:2019-01-06 出版日期:2019-02-28 发布日期:2019-03-18

MiR-122 induces apoptosis of glioma cells by targeting RUNX2

  1. Department of Neurology, Sichuan People’s Hospital, Sichuan Academy of Medical Sciences, Chengdu 610100, China

  • Received:2018-11-02 Revised:2019-01-06 Online:2019-02-28 Published:2019-03-18

摘要:

目的 探讨微小RNA122(miR-122)对神经胶质瘤细胞凋亡的影响及可能分子机制。方法 采用荧光定量PCR(QPCR)检测人正常星形胶质细胞系HA1800和胶质瘤细胞系U251、U87、SHG44、MO59K中miR-122的表达情况。双荧光素酶报告实验评价miR-122对RUNX2的靶向调控作用。向U251细胞转染miR-122 mimics(miR-122组)和阴性对照NC(NC组),流式细胞术检测细胞凋亡,Western blotting检测凋亡相关蛋白Bcl-2、Bax、cleaved caspase-3的表达。向U251细胞同时转染miR-122 mimics和siRUNX2(miR-122+siRUNX2组),流式细胞术检测细胞凋亡。结果 U251、U87、SHG44、MO59K细胞系中miR-122表达水平分别为0.34±0.052、0.65±0.061、0.59±0.071和0.69±0.098,显著低于正常星形胶质细胞系HA1800的1.17±0.173,差异具有统计学意义(P<0.05)。miR-122可抑制野生型RUNX2 3’UTR报告基因载体的荧光素酶活性,而对突变型RUNX2 3’UTR-MUT的荧光素酶活性无影响。miR-122组U251细胞凋亡率为(23.77±0.83)%,高于NC组的(6.17±0.12)%,差异具有统计学意义(P<0.05);低于miR-122+siRUNX2组的(70.85±0.35)%(P<0.05)。Western blotting检测结果显示,miR-122组RUNX2蛋白表达量为0.57±0.048,低于NC组的1.21±0.19(P<0.05)。与NC组比较,miR-122组Bax(3.47±0.077)、 cleaved caspase-3(4.38±0.121)表达均明显上调,而Bcl-2(0.39±0.104)明显下调(P<0.05)。结论  miR-122可以通过靶向RUNX2促进线粒体凋亡通路的激活,促进神经胶质瘤细胞凋亡。

关键词:

神经胶质瘤')">"> 神经胶质瘤, miR-122, RUNX2, 凋亡

Abstract: Objective  To investigate the effect of microRNA122 (miR-122) on apoptosis of glioma cells and its possible molecular mechanism. Methods The expression of miR-122 in human normal astrocyte lines HA1800 and glioma cell lines U251, U87, SHG44 and MO59K was detected by quantitative fluorescence PCR (QPCR). Dual luciferase reporter assay was used to evaluate the targeting effect of miR-122 on RUNX2. MiR-122 mimics (miR-122 group)and negative control NC(NC group) were transfected into U251 cells. Apoptosis was detected by flow cytometry. Western blotting was used to detect the expression of Bcl-2,Bax and cleaved caspase-3 protein in two groups. MiR-122 mimics and siRUNX2 (MiR-122+siRUNX2 group) were simultaneously transfected into U251 cells. Apoptosis was detected by flow cytometry. Results The expression of miR-122 in U251,U87,SHG44 and MO59K cell lines were 0.34±0.052, 0.65±0.061, 0.59±0.071 and 0.69±0.098, which was significantly lower than that of human normal astrocyte lines HA1800 (1.17±0.173), and the difference was statistically significant (P<0.05).MiR-122 inhibited the luciferase activity of wild-type RUNX2 3’UTR reporter gene vector, but had no effect on the luciferase activity of mutant RUNX2 3’UTR reporter gene vector. The apoptotic rate of U251 cells in miR-122 group was (23.77 ±0.83)%, higher than that in NC group (6.17 ±0.12)%, lower than that in miR-122+siRUNX2 group (70.85±0.35)%.The difference was statistically significant (P<0.05). Western blotting Results  showed that the expression of RUNX2 protein in the miR-122 group was 0.57±0.048, which was lower than that in the NC group (1.21±0.19), with statistical significance (P<0.05). Compared with NC group, the expressions of Bax and cleaved caspase-3 were significantly up-regulated in miR-122 group, while Bcl-2 was significantly down-regulated (P<0.05). Conclusion MiR-122 can promote the activation of mitochondrial apoptosis pathway by targeting RUNX2, thereby promoting apoptosis of glioma cells.

Key words: Glioma, miR-122, RUNX2, Apoptosis

中图分类号: 

  • R739.41
[1] 牛 虹, 田同德, 唐静雯, 岳光星, 李华华, 范伊晓, 周浩本.

微小RNA-148a-3p靶向调控MAP3K9表达及对胃癌细胞增殖和凋亡的影响 [J]. 临床肿瘤学杂志, 2019, 24(2): 108-112.

[2] 程春来, 丁 雯, 车 元.

YKL-40调控子宫内膜癌顺铂化疗耐药性的实验研究 [J]. 临床肿瘤学杂志, 2019, 24(2): 113-118.

[3] 何灏澜, 李 倩, 姜 晗, 王 晓, 陆 明.

光辉霉素对胃癌细胞周期、凋亡的影响及可能机制 [J]. 临床肿瘤学杂志, 2019, 24(2): 133-136.

[4] 魏 蕾, 李自雄, 秦叔逵, 刘秀峰.

吉西他滨单药或联合白蛋白结合型紫杉醇治疗东亚人群晚期胰腺癌临床疗效的荟萃分析 [J]. 临床肿瘤学杂志, 2019, 24(2): 137-144.

[5] 张 宁, 卢创新, 务 森, 何 苡, 魏 立.

miR-138-5p在非小细胞肺癌中的表达及临床意义 [J]. 临床肿瘤学杂志, 2019, 24(2): 149-152.

[6] 杨晋生, 古选民, 方军超.

胶质瘤MGMT启动子甲基化及其临床意义 [J]. 临床肿瘤学杂志, 2019, 24(2): 153-157.

[7] 李振淼, 宋 博, 赵 怡.

X射线调强放疗对乳腺癌保乳术后远期生存及免疫功能影响的临床观察 [J]. 临床肿瘤学杂志, 2019, 24(2): 158-162.

[8] 刘政操, 陈清清, 袁光达, 朱佳浩, 吴锦昌, 冀胜军. 中性粒细胞/淋巴细胞比值评估老年食管癌放疗预后的价值[J]. 临床肿瘤学杂志, 2019, 24(2): 167-170.
[9] 王 莹, 张同梅, 董宇杰, 李宝兰. 24例胸腺鳞癌的临床分析[J]. 临床肿瘤学杂志, 2019, 24(2): 171-174.
[10] 黄博杰, 何信佳, 赵园园.

紫杉醇联合铂类治疗晚期胰腺腺鳞癌1例 [J]. 临床肿瘤学杂志, 2019, 24(2): 188-189.

Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 钟克力1,张 丽2,戴 勇2,周汉新2,王春友1. 采用染色质免疫沉淀联合芯片技术分析胃癌全基因组蛋白H3K27三甲基化水平[J]. 临床肿瘤学杂志, 2009, 14(1): 15 .
[2] 钱 莘1,丁金勇2,吕 军1,陈正堂2. CCA+SP-C+细胞和CD133+细胞在人肺腺癌组织分布的初步研究[J]. 临床肿瘤学杂志, 2009, 14(1): 6 .
[3] 杨 斌,陈赛英,史佃云,张佃乾. 宫颈癌术前介入化疗前后组织中Survivin、Caspase-3和Caspase-7的表达变化及意义[J]. 临床肿瘤学杂志, 2009, 14(1): 39 .
[4] 侯 军,章卫平,邱慧颖,郑晓丽,王利平,倪 雄,宋献民,王健民. 自体外周血干细胞移植治疗T细胞淋巴瘤的临床研究[J]. 临床肿瘤学杂志, 2009, 14(2): 102 .
[5] 陈 建1,许 林1. 局部晚期非小细胞肺癌的外科治疗现状[J]. 临床肿瘤学杂志, 2009, 14(2): 183 .
[6] 刘扬清1,高 勇1,万一元1,易竹筠1,惠红霞1,徐丽娟1,刘 华1. 大蒜素对结肠癌LoVo细胞增殖的影响[J]. 临床肿瘤学杂志, 2009, 14(2): 139 .
[7] 李建军,黄海辉,潘 凤,边志衡,胡绍毅,梁后杰. 透明质酸酶增强5-FU对结肠癌抗癌作用的动物实验研究[J]. 临床肿瘤学杂志, 2009, 14(2): 134 .
[8] 时淑珍1,赵俊军2,赵卫红1,徐晓辉1. FHIT和mdm2蛋白在非小细胞肺癌中的表达及意义[J]. 临床肿瘤学杂志, 2009, 14(3): 212 .
[9] 王乐纯1,杨 强2,马成海1. 小儿骶尾部畸胎瘤的手术治疗[J]. 临床肿瘤学杂志, 2009, 14(3): 242 .
[10] 何义富,孙玉蓓,陈 健,徐腾云,王 刚,王 勇,杜建平,
陈曼萍,江丰收,胡长路,季楚舒,胡 冰
. 腹腔内应用重组人血管内皮抑制素联合氟尿嘧啶治疗恶性腹水的初步探讨[J]. 临床肿瘤学杂志, 2009, 14(3): 252 .